Publication
  • ESPN •
  • 2 October, 2026 •
  • •

Real-world effectiveness and safety of pegcetacoplan in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: PRISM-C3, a multi-country Phase 4 study

David Kavanagh, Matthew C Pickering, Terence Cook, Marina Vivarelli, Moglie Le Quintrec, Véronique Frémeaux-Bacchi, Virginia Taliadouros, Elena Surova, Nicholas Webb, Fadi Fakhouri

Publication
  • ESPN •
  • 2 October, 2026 •
  • •

Pegcetacoplan treatment response in VALIANT/VALE: Impact of genetic and acquired complement dysregulation and disease type in C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis

Nicole Van De Kar, Marina Norris, Daniel P Gale, Sophie Chauvet, Fernando Caravaca-Fontán, Julia Weinmann-Menke, Bradley P Dixon, Carla M Nester, Lucía Quintana-Gallardo, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Fadi Fakhouri

Publication
  • ESPN •
  • 2 October, 2026 •
  • •

Pegcetacoplan sustained clinical benefit in adolescent patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis through 1 year of therapy: Data from VALIANT/VALE

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Naoya Fujita, Antonio Mastrangelo, Nabil Melhem, Nicole Van De Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Kathryn Gordon, Zhongshen Wang, Carla M Nester

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Epidemiology of C3G and primary IC-MPGN: a systematic literature review and meta-analysis

Fernando Caravaca-Fontán, Carly Rich, Veruska Carboni, Jameel Nazir, Chris D Poole, Daniel P Gale

Available materials

Poster
Sign up for alerts